title: Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review.
abstract: In the past, chemotherapeutic treatment of patients with high grade malignant gliomas following surgery and radiation has not added significantly to the 12-14 month median survival rate. Over four years, 37 patients with high grade malignant gliomas underwent 246 treatment procedures with a combination of methotrexate, cyclophosphamide, and procarbazine given in association with hyperosmolar mannitol-induced transient breakdown of the blood-brain barrier. These patients have demonstrated a median survivorship of 22 months after considering age, Karnofsky Performance Score, and necrosis by the Cox Proportional Hazards model. The study group had a mean age of 43 years, and mean Karnofsky Performance Score of 67%. Sixty-five percent of the procedures had well-documented barrier disruption. Sixteen percent remained in complete remission while 24 patients (65%) had partial or temporary remission. Progression-free intervals after blood-brain barrier disruption/chemotherapy ranged from 1-47 (mean 15) months. Neurotoxicity has been minimal with one peri-procedural mortality and five patients suffering an increase in neurologic deficit after a procedure. The results of this study are consistent with and further extend the reported literature on this method of brain tumor therapy as described in other centers. Chemotherapy in conjunction with osmotic disruption of the blood-brain barrier may provide the pharmacokinetic advantage sufficient to significantly improve survival in patients with high grade malignant glioma.
authors.affiliation: Division of Neurosurgery, University of Missouri-Columbia 65212.
authors.forename: M K
authors.initials: MK
authors.lastname: Gumerlock
authors.forename: B D
authors.initials: BD
authors.lastname: Belshe
authors.forename: R
authors.initials: R
authors.lastname: Madsen
authors.forename: C
authors.initials: C
authors.lastname: Watts
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D005910:Glioma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D008353:Mannitol / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage; D009336:Necrosis; D011344:Procarbazine / Q000008:administration & dosage; D012189:Retrospective Studies; D016284:Technetium Tc 99m Pentetate; D014057:Tomography, X-Ray Computed
chemical_list: D011344:Procarbazine; D008353:Mannitol; D003520:Cyclophosphamide; D016284:Technetium Tc 99m Pentetate; D008727:Methotrexate